Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Common Equity (2022 - 2025)

Historic Common Equity for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $450.9 million.

  • Day One Biopharmaceuticals' Common Equity fell 1883.02% to $450.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $450.9 million, marking a year-over-year decrease of 1883.02%. This contributed to the annual value of $502.8 million for FY2024, which is 4507.73% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Common Equity of $450.9 million as of Q3 2025, which was down 1883.02% from $460.8 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Common Equity's 5-year high stood at $555.5 million during Q3 2024, with a 5-year trough of $259.6 million in Q1 2022.
  • Moreover, its 4-year median value for Common Equity was $389.6 million (2023), whereas its average is $390.7 million.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Common Equity plummeted by 2800.65% in 2024 and then skyrocketed by 6155.74% in 2025.
  • Day One Biopharmaceuticals' Common Equity (Quarter) stood at $332.0 million in 2022, then increased by 4.37% to $346.5 million in 2023, then soared by 45.08% to $502.8 million in 2024, then fell by 10.32% to $450.9 million in 2025.
  • Its Common Equity was $450.9 million in Q3 2025, compared to $460.8 million in Q2 2025 and $479.5 million in Q1 2025.